Analgesia for patients with advanced disease: I

Postgraduate Medical Journal

Volumn 80, Issue 941, 2004, Pages 148-154

  Hall, E J ^a   Sykes, N P ^a  

^a ST CHRISTOPHER S HOSPICE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; ANESTHETIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIRETROVIRUS AGENT; BISPHOSPHONIC ACID DERIVATIVE; BUPRENORPHINE; CODEINE; DIAMORPHINE; DIHYDROCODEINE; FENTANYL; HYDROMORPHONE; METHADONE; MORPHINE; NALOXONE; NONSTEROID ANTIINFLAMMATORY AGENT; ONDANSETRON; OPIATE; OXYCODONE; PARACETAMOL; PSYCHOSTIMULANT AGENT; SPASMOLYTIC AGENT; TRAMADOL;

ACUPUNCTURE; ADJUVANT THERAPY; ALTERNATIVE MEDICINE; ANALGESIA; ANESTHESIA; ARTICLE; BENIGN TUMOR; CANCER PAIN; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; COGNITIVE THERAPY; CONFUSION; CONSTIPATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG MECHANISM; DRUG METABOLISM; DYING; EPIDEMIOLOGICAL DATA; HALLUCINATION; HEALTH PRACTITIONER; HEART FAILURE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MASSAGE; MEDICAL ASSESSMENT; NAUSEA; NEUROPATHOLOGY; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRURITUS; RESPIRATION DEPRESSION; REVIEW; SEDATION; SIDE EFFECT; SLOW DRUG RELEASE; SYMPTOM; TABLET FORMULATION; TRANSCUTANEOUS NERVE STIMULATION; URINE RETENTION; VOMITING; WORLD HEALTH ORGANIZATION; XEROSTOMIA;

ANALGESIA; CHRONIC DISEASE; COMPLEMENTARY THERAPIES; HUMANS; LEGISLATION, DRUG; MORPHINE; NARCOTICS; NEOPLASMS; PAIN; TERMINOLOGY; TRANSCUTANEOUS ELECTRIC NERVE STIMULATION;

EID: 1642325760     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2003.015511     Document Type: Review

References (36)

1. Higginson IJ. Innovations in assessment: epidemiology and assessment of pain in advanced cancer. In: Jensen TS, Turner JA, Wiesenfeld-Hallin Z, eds. Proceedings of the 8th world congress on pain: progress in pain research and management. Seattle, WA: IASP Press, 1997:707-16.
2. Weiss SC, Emanuel LL, Fairclough DL, et al. Understanding the experience of pain in terminally ill patients. Lancet 2001;357:1311-15.
3. World Health Organization. Cancer pain relief. 1st Ed. Geneva: World Health Organisation, 1986.
4. Banning A, Sjogren P, Henriken H. Pain causes in 200 patients referred to a multidisciplinary cancer pain clinic. Pain 1991;45:45-8.
5. International Association for the Study of Pain. Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the International Association for the Study of Pain Task Force, Subcommittee on Taxonomy. Pain Suppl 1986;3:1-226S (www.iasp-pain.org).
6. Stucky CL, Gold MS, Zhang X. Mechanisms of pain. Proc Natl Acad Sci U S A 2001;98:11845-6.
7. Yaksh TL. New horizons in our understanding of the spinal physiology and pharmacology of pain processing. Semin Oncol 1993;20(2 suppl 1 ):6-18.
8. Dickenson AH. Spinal cord pharmacology of pain. Br J Anaesth 1995;75:193-200.
9. Hearn J, Higginson IJ. Development and validation of a core outcome measure for palliative care: the palliative care core outcome scale. The palliative care core audit project advisory group. Qual Health Care 1999;8:219-27.
10. British Association of Surgical Oncology. British Association of Surgical Oncology Guidelines. The management of metastatic bone disease in the United Kingdom. The Breast Specialty Group of the British Association of Surgical Oncology. Eur J Surg Oncol 1999;25:3-23.
11. Weill A, Kobaiter H, Chiras J. Acetabulum malignancies: technique and impact on pain of percutaneous injection of acrylic surgical cement. Eur Radiol 1998;8:123-9.
12. Gaze MN, Kelly CG, Kerr GR, et al. Pain relief and quality of life following radiotherapy for bone metastases: a randomised trial of two fractionation schedules. Radiother Oncol 1997;45:109-16.
13. Vermeulen SS. Whole brain radiotherapy in the treatment of metastatic brain tumours. Semin Surg Oncol 1998;14:64-9.
14. Kaptchuk TJ. Acupuncture. Theory, efficacy and practice. Ann Intern Med 2002;136:374-83.
15. Pan CX, Morrison RS, Ness J, et al. Complementary and alternative medicine in the management of pain, dyspnoea and nausea and vomiting near the end of life: a systematic review. J Pain Symptom Manage 2000;20:374-87.
16. Jadad AR, Browman GP. The WHO analgesic ladder for cancer pain management: stepping up the quality of its evaluatbn. JAMA 1995;274:1870-3.
17. The Association for Palliative Medicine and the Pain Society. The use of drugs beyond licence in palliative care and pain management. A position statement prepared on behalf of the Association for Palliotive Medicine and the Pain Society. The Association for Palliative Medicine and the Pain Society, 2002.
18. Hanks GW, de Conno F, Cherny N, et al. Expert Working Group of the Research Network of the European Association for Palliative Care. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001;84:587-93.
19. Scottish Intercollegiate Guidelines Network. Control of pain in patients with cancer, No 44. Edinburgh: Scottish Intercollegiate Guidelines Network (SIGN), 2000 (www.sign.ac.uk/guidelines).
20. Pasternak GW. Pharmacological mechanisms of opioid analgesics. Clin Neuropharmacol 1993;16:1-18.
21. Brosen K, Sindrup SH, Skjelbo E, et al. Role of genetic polymorphism in psychopharmacology: an update. Psychopharmacol Ser 1993;10:199-211.
22. Watson C, Babul N. Efficacy of oxycodone in neuropathic pain: a randomised trial in postherpetic neuralgia. Neurology 1998;50:1837-41.
23. Dellemijn P. Are opioids effective in relieving neuropathic pain? Pain 1999;80:453-62.
24. Hanks G. Oral transmucosal fentanyl citrate for the management of breakthrough pain. Eur J Palliat Care 2001;8:6-9.
25. Kendall JM, Reeves BC, Latter VS. Multicentre randomised controlled trial of nasal diamorphine for analgesia in children and teenagers with clinical fractures. BMJ 2001;322:261-5.
26. Krajnik M, Zylicz Z, Finlay I, et al. Potential uses of topical opioids in palliative care: repart of 6 cases. Pain 1999;80:121-5.
27. Todd J, Rees E, Gwilliam B, et al. An assessment of the efficacy and tolerability of a "double dose" of immediate release morphine at bedtime. Palliat Med 2002;16:507-12.
28. British Medical Association/Royal Pharmaceutical Society of Great Britain. British national formulary. London: BMA/Royal Pharmaceutical Society of Great Britain, number 45, March 2003 (www.bnf.org.uk).
29. Cherny N, Ripamonti C, Pereira J, et al. Expert working group of the European Association for Palliative Care. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001;19:2542-54.
30. Payne R, Mathias SD, Pasta DJ, et al. Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol 1998;16:1588-93.
31. Sykes NP. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med 1996;10:135-44.
32. Foss JF. A review of the potential role of methylnaltrexone in opioid bowel dysfunction. Am J Surg 2001;182(5A suppl):19-26S.
33. Bruera E, Chadwick S, Brenneis C, et al. Melhylphenidate associated with narcotics for the treatment of cancer pain. Cancer Treat Rep 1987;71:67-70.
34. Borgeat A, Stirnemann HR. Ondansetron is effective to treat spinal or epidural morphine induced pruritus. Anesthesiology 1999;90:432-6.
35. de Stoutz ND, Bruera E, Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995;10:378-84.
36. Hall EJ, Sykes NP. Analgesia for patients with advanced disease: 2. Postgrad Med J 2004;80 (in press).